Lab
Quest Diagnostics Clinical Laboratories INC
Quest Diagnostics Clinical Laboratories INC was paid $7.60M by Medicaid between Apr 2020 and Dec 2024, across 188 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 21% of everything it billed.
33Billing provider infoQUEST DIAGNOSTICS CLINICAL LABORATORIES INC
FLINT, MI 48504
FLINT, MI 48504
33aNPI1033749940assigned 01/20/2020
33bProvider typeClinical Medical Laboratory
28Total paid$7.60M
24GClaims499,955
24DCodes billed188
24AFirst – last monthApr 2020 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Michigan
Rank by total paid#16 of 108
Median peer was paid$588K
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BOWLES, CHARLES controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 100,883 | $1.65M | |
| 2021 | 178,277 | $2.80M | |
| 2022 | 123,963 | $1.86M | |
| 2024incomplete | 96,832 | $1.29M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 21% | 16,060 | 15,241 | $1.56M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 6.7% | 16,210 | 12,658 | $505K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 5.9% | 9,272 | 7,536 | $449K |
| 81513 | 5.0% | 3,232 | 3,187 | $379K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 4.4% | 9,711 | 9,559 | $335K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.3% | 18,683 | 18,013 | $330K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 4.2% | 4,711 | 3,349 | $321K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.1% | 18,579 | 17,895 | $310K |
| 80050 | General health panel | 3.0% | 14,625 | 14,555 | $226K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.9% | 15,982 | 15,899 | $219K |
| 80061 | Lipid panel | 2.8% | 31,448 | 31,305 | $215K |
| 87799 | 2.5% | 4,805 | 4,660 | $190K |
176 more codes
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 2.0% | 10,600 | $148K |
| 80053 | Comprehensive metabolic panel | 1.9% | 23,749 | $144K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.5% | 5,785 | $116K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.5% | 13,968 | $116K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 24,306 | $108K |
| 86769 | 1.4% | 2,407 | $106K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1.3% | 6,383 | $99K |
| 86480 | 1.1% | 2,331 | $84K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.1% | 21,168 | $83K |
| 87512 | <1% | 4,699 | $61K | |
| 86003 | <1% | 1,013 | $61K | |
| 82607 | <1% | 6,319 | $55K | |
| 86803 | <1% | 6,692 | $50K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,029 | $49K |
| 80081 | <1% | 1,145 | $48K | |
| 83013 | <1% | 1,176 | $46K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 185 | $45K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 10,154 | $41K |
| 82746 | <1% | 4,725 | $40K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,865 | $39K |
| 84439 | <1% | 7,259 | $34K | |
| 82728 | <1% | 5,191 | $33K | |
| 86235 | <1% | 661 | $33K | |
| 87088 | <1% | 7,805 | $32K | |
| 84153 | <1% | 3,445 | $32K | |
| 84403 | <1% | 1,765 | $26K | |
| 80074 | <1% | 2,242 | $26K | |
| 86696 | <1% | 1,817 | $25K | |
| 87522 | Neg quan hep c or qual rna | <1% | 911 | $22K |
| 85027 | <1% | 5,934 | $22K | |
| 87536 | <1% | 458 | $21K | |
| 82652 | <1% | 1,429 | $20K | |
| 87340 | <1% | 3,740 | $20K | |
| 83550 | <1% | 4,816 | $19K | |
| 88142 | <1% | 1,613 | $19K | |
| 86592 | <1% | 7,636 | $19K | |
| 81001 | <1% | 9,971 | $18K | |
| 83001 | <1% | 1,601 | $17K | |
| 86038 | <1% | 2,313 | $16K | |
| 86695 | <1% | 1,736 | $16K | |
| 82043 | <1% | 4,879 | $16K | |
| 83540 | <1% | 5,188 | $16K | |
| 82670 | <1% | 984 | $16K | |
| 82570 | <1% | 5,493 | $15K | |
| 83655 | <1% | 2,108 | $15K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,172 | $15K |
| 87800 | <1% | 1,434 | $15K | |
| 83002 | <1% | 1,306 | $14K | |
| 87186 | <1% | 2,814 | $14K | |
| 84146 | <1% | 1,253 | $14K | |
| 87070 | <1% | 2,726 | $14K | |
| 88141 | <1% | 950 | $13K | |
| 87077 | <1% | 2,766 | $13K | |
| 83735 | <1% | 3,398 | $13K | |
| 84402 | <1% | 799 | $12K | |
| 84702 | <1% | 2,754 | $12K | |
| 84481 | <1% | 1,126 | $11K | |
| 83970 | <1% | 486 | $11K | |
| 84550 | <1% | 4,009 | $11K | |
| 86364 | <1% | 145 | $10K | |
| 87563 | <1% | 425 | $9K | |
| 82785 | <1% | 787 | $8K | |
| 86140 | <1% | 2,286 | $7K | |
| 86200 | <1% | 889 | $7K | |
| 86704 | <1% | 1,093 | $7K | |
| 86376 | <1% | 745 | $6K | |
| 86787 | <1% | 822 | $6K | |
| 86706 | <1% | 1,115 | $6K | |
| 82627 | <1% | 446 | $6K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 26 | $6K |
| 84436 | <1% | 2,002 | $6K | |
| 87081 | <1% | 1,466 | $6K | |
| 83520 | <1% | 1,097 | $5K | |
| 86708 | <1% | 872 | $5K | |
| 83525 | <1% | 785 | $5K | |
| 86431 | <1% | 1,541 | $5K | |
| 83880 | <1% | 232 | $5K | |
| 86360 | <1% | 188 | $5K | |
| 83690 | <1% | 1,191 | $5K | |
| 86780 | <1% | 628 | $5K | |
| 84480 | <1% | 711 | $5K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 67 | $5K |
| 84479 | <1% | 1,479 | $4K | |
| 86317 | <1% | 512 | $4K | |
| 87147 | <1% | 1,379 | $4K | |
| 84460 | <1% | 1,413 | $4K | |
| 85652 | <1% | 2,638 | $4K | |
| 82950 | <1% | 1,506 | $4K | |
| 84270 | <1% | 459 | $4K | |
| 82565 | <1% | 1,402 | $4K | |
| 80051 | <1% | 963 | $4K | |
| 82105 | <1% | 505 | $4K | |
| 84450 | <1% | 1,311 | $4K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 43 | $4K |
| 86762 | <1% | 435 | $4K | |
| 83020 | <1% | 497 | $4K | |
| 84144 | <1% | 300 | $4K | |
| 87902 | <1% | 24 | $4K | |
| 84100 | <1% | 1,307 | $4K | |
| 82550 | <1% | 916 | $3K | |
| 83516 | <1% | 673 | $3K | |
| 82150 | <1% | 875 | $3K | |
| 86225 | <1% | 400 | $3K | |
| 81511 | <1% | 50 | $3K | |
| 83014 | <1% | 675 | $3K | |
| 80076 | <1% | 640 | $3K | |
| 82248 | <1% | 1,022 | $3K | |
| 86039 | <1% | 445 | $3K | |
| 85610 | <1% | 1,707 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 183 | $3K |
| 84154 | <1% | 271 | $3K | |
| 84520 | <1% | 1,245 | $3K | |
| 86800 | <1% | 278 | $3K | |
| 82947 | <1% | 1,134 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 48 | $2K |
| 82310 | <1% | 824 | $2K | |
| 82784 | <1% | 307 | $2K | |
| 83021 | <1% | 230 | $2K | |
| 84156 | <1% | 1,050 | $2K | |
| 87625 | <1% | 96 | $2K | |
| 86160 | <1% | 147 | $2K | |
| 82977 | <1% | 482 | $2K | |
| 84703 | <1% | 389 | $2K | |
| 82465 | <1% | 682 | $2K | |
| 84681 | <1% | 118 | $1K | |
| 85730 | <1% | 837 | $1K | |
| 83721 | <1% | 243 | $1K | |
| 83615 | <1% | 363 | $1K | |
| 80164 | <1% | 155 | $1K | |
| 82951 | <1% | 165 | $1K | |
| 86850 | <1% | 496 | $1K | |
| 82040 | <1% | 350 | $872.24 | |
| 86008 | <1% | 12 | $845.12 | |
| 86900 | <1% | 500 | $828.78 | |
| 85018 | <1% | 627 | $807.09 | |
| 86901 | <1% | 483 | $799.21 | |
| 85660 | <1% | 236 | $737.99 | |
| 84075 | <1% | 265 | $714.27 | |
| 85014 | <1% | 468 | $592.50 | |
| 83498 | <1% | 38 | $586.08 | |
| 87205 | <1% | 239 | $585.85 | |
| 82247 | <1% | 184 | $452.74 | |
| 86812 | <1% | 27 | $419.70 | |
| 81015 | <1% | 239 | $399.12 | |
| 81003 | <1% | 319 | $385.80 | |
| 84155 | <1% | 208 | $380.06 | |
| 86255 | <1% | 63 | $365.04 | |
| 82533 | <1% | 39 | $361.00 | |
| 86147 | <1% | 34 | $329.70 | |
| 86705 | <1% | 129 | $257.60 | |
| 87075 | <1% | 40 | $218.49 | |
| 86709 | <1% | 128 | $216.21 | |
| 87481 | <1% | 13 | $195.03 | |
| 82952 | <1% | 80 | $179.64 | |
| 84478 | <1% | 52 | $145.55 | |
| 87102 | <1% | 29 | $142.10 | |
| 82274 | <1% | 15 | $139.20 | |
| 83090 | <1% | 13 | $135.46 | |
| 83718 | <1% | 27 | $123.10 | |
| 86593 | <1% | 46 | $117.28 | |
| 80069 | <1% | 26 | $112.98 | |
| 86141 | <1% | 14 | $98.97 | |
| 85045 | <1% | 40 | $83.23 | |
| 80178 | <1% | 14 | $50.18 | |
| 85007 | <1% | 24 | $46.00 | |
| 84132 | <1% | 46 | $25.56 | |
| 84295 | <1% | 43 | $23.84 | |
| 82435 | <1% | 41 | $17.04 | |
| 82374 | <1% | 40 | $15.10 | |
| 85041 | <1% | 40 | $5.58 | |
| 85049 | <1% | 38 | $2.76 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 620 | $0.10 |
| 82172 | 0% | 37 | $0.00 | |
| 85060 | 0% | 89 | $0.00 | |
| 85048 | 0% | 37 | $0.00 | |
| 85004 | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOWLES, CHARLES (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.